

Cinnamon, Clove and Cumin against Urinary Tract Infections

Subjects: Urology & Nephrology

Contributor: Ariadna Jazmín Ortega-Lozano, Estefani Yaquelin Hernández-Cruz, Tania Gómez-Sierra, José Pedraza-Chaverri

Spices are aromatic plants widely used in Mexico to flavor, color, or preserve food. In particular, the Food and Drug Administration (FDA) Organization defined *spices* as: “whole, broken or ground aromatic vegetable substances, whose significant function in food is to flavor rather than to nourish”. Most of the beneficial health properties of spices are mediated through the direct action of their phytochemicals, especially polyphenols or polyphenol degradation products. These phytochemicals have broad antioxidant properties and target specific receptors or enzymes involved in various anti-inflammatory pathways or immune responses. Phenolic acids and flavonoids, especially flavones and flavonoids, are spices' predominant class of polyphenols. Furthermore, the antimicrobial properties of spices are attributed to their unique volatile oils and oleoresins. Because spices are obtained from aromatic plants and herbs, they are generally considered safe (GRAS).

Keywords: cinnamon ; cloves ; cumin ; urinary tract infections ; antimicrobial activity

1. Introduction

Urinary tract infections (UTIs) are among the most common bacterial infections. Worldwide, in 2019, it was estimated that 404.61 million cases and 236,790 deaths were associated with UTIs ^[1]. Regarding Mexico, the picture is similar, UTIs are one of the most common pathologies, and approximately 4 million cases are reported each year, and it is the third most common cause of morbidity ^[2]. UTIs can affect both males and females, but the prevalence is higher in females (>70%) due to the very close presence of the urethra to the anus and the gastrointestinal colonization of pathogens in the vagina ^[3]. UTIs are an inflammatory response of the urothelium to bacterial infection, and it involves pyelonephritis (kidney infection), urethritis (ureters infection), cystitis (bladder infection), and prostatitis ^[3]. UTIs are caused by bacteria, viruses, and yeast, although bacteria cause more than 85% of infections. Among the bacteria most commonly associated with UTIs are *Escherichia coli*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Enterococcus faecalis*, *Pseudomonas aeruginosa*, *Proteus mirabilis*, *Acinetobacter baumannii*, and *Staphylococcus saprophyticus* ^[4]. It is worth mentioning that UTIs are considered established when the pathogen can enter the urinary tract system and reach more than 10⁵ colony/mL in the urine ^[4]. *E. coli* and *Enterococcus* spp. are the most frequent bacteria in UTIs. Both bacteria are present in the gastrointestinal habitat, which favors acquiring resistance genes from other commensal organisms ^[5]. Bacterial resistance and recurrence are due to the misuse and abuse of antibiotics and the adherence capacity of uropathogens that allows them to internalize in target cells, forming biofilm ^{[2][6][7]}. Furthermore, catheters are estimated to be one of the most common causes of healthcare-associated infection, as it is known that bacteria can form biofilms on catheters, making the control of bacterial biofilm formation an urgent need ^{[8][9]}.

2. Cinnamon

The trees and shrubs of the *Cinnamomum* genus belong to the Lauraceae family and contain around 300 species worldwide. The most common are *C. burmanni*, *C. camphora*, *C. cassia*, *C. osmophloeum*, *C. verum*, and *C. zeylanicum* ^{[10][11][12][13]}. The fruit, leaf, and bark of the cinnamon tree contain bioactive compounds such as cinnamyl acetate, coumarin, eugenol, eucalyptol, *trans*-cinnamaldehyde, L-borneol, caryophyllene oxide, benzoic acid, linalool, caffeic acid, and camphor ^{[11][13][14][15]}. Cinnamon leaves and the bark have been reported to have antioxidant activity ^[12]. However, the peeled and dried bark is a popular spice used as a condiment and flavoring agent in desserts, spicy sweets, tea, liqueurs, cereals, bread, fruit, and chocolates. Mexico is the biggest importer of *C. zeylanicum*, also known as true cinnamon ^[16], and it is also used in chocolate production and sweet and savory dishes. Moreover, cinnamon is used in traditional medicine worldwide due to its antimicrobial, antifungal, nematicidal, antipyretic, insecticidal, antioxidant, and antidiabetic properties ^{[11][12][14][17][18][19]}. Although cinnamon is recognized as a safe spice, with a tolerable daily intake of 0.1 mg/kg/day, adverse effects such as stomach and bowel disorders and allergic reactions have been described ^{[16][20]}.

The solvents used to extract the bioactive compounds of cinnamon are water, methanol, ethanol, and chloroform [15]. Hydrodistillation, steam distillation, Soxhlet extraction, and maceration are the most common methods to prepare cinnamon extract oils from leaf, fruit, and bark. Nevertheless, novel extraction methods such as supercritical fluid, assisted by microwave radiation, superheated water, supercritical carbon dioxide (CO₂), or ultrasounds have been developed [15][17][21]. The essential oils (EOs) are obtained from bark through hydrodistillation, steam distillation, and supercritical fluid extraction techniques. EOs extracted contain *trans*-cinnamaldehyde, eugenol, cinnamyl acetate, camphor, and linalool, representing about 85% of the total oil composition [17][22]. However, *trans*-cinnamaldehyde is an unstable compound that can be oxidized to cinnamic acid when exposed to air, losing the acrolein group, which is responsible for antimicrobial activity. Nevertheless, the other bioactive compounds in cinnamon EO have antimicrobial activity and synergistic or additive effects with *trans*-cinnamaldehyde [11][23][24].

The bioactive compounds in cinnamon EO, such as *trans*-cinnamaldehyde, pass through bacteria cell walls, altering the permeability and integrity of the membrane and, consequently, causing loss of transporting proteins, metabolites, and ions which leads to cytoplasmic coagulation and denaturation of proteins [11][25][26][27]. Moreover, *trans*-cinnamaldehyde downregulated the F1F0-ATPase complex, inducing the depletion of intracellular adenosine triphosphate (ATP) synthesis and growth rate. Furthermore, *trans*-cinnamaldehyde causes energy deprivation, amino acid decarboxylation activity inhibition within the cells, and cell death [11][26]. The antimicrobial activity of cinnamon bark extracts is shown in **Table 1**.

It has been described that the EO of *C. cassia* obtained by hydrodistillation has a minimum inhibitory concentration (MIC) against bacterial strains collected from patients with UTIs, such as *E. coli* in the range of 0.30 to 2.50 mg/mL, *P. aeruginosa* to 2.5 to 5.0 mg/mL, *P. mirabilis* 0.30 to 1.25 mg/mL, and *K. pneumoniae* to 0.16 to 31 mg/mL. In addition, this EO has inhibition zones around 12 to 39 mm for Gram-negative bacteria strains [28].

Moreover, cinnamon bark oil (*C. zeylanicum*) has inhibitory and bactericidal activity against *P. aeruginosa* and its multidrug-resistant strains isolated from patients with UTIs. The MIC and minimal bactericidal concentrations (MBC) values are in the range of 0.1125 to 0.225% (v/v) and 0.1125 to 1.8%, respectively. Moreover, cinnamon bark oil has a synergistic interaction with some antibiotics. The main bioactive compounds identified in this cinnamon bark oil are *trans*-cinnamaldehyde and eugenol. However, *trans*-cinnamaldehyde possessed better antimicrobial activity to reduce 6 log CFU/mL to this pathogen [27].

In addition, ethanolic extract of *C. zeylanicum* could inhibit the growth of colonies of *E. coli*, *P. aeruginosa*, and *K. pneumoniae* obtained from urine samples of patients with UTIs. The results indicate that the mean zone of inhibition against the pathogens mentioned before is 11.72 mm, 20.16 mm, and 25.50 mm, respectively. This inhibition zone is similar to norfloxacin, a common antibiotic for treating UTIs. Although *trans*-cinnamaldehyde has been identified as the bioactive antimicrobial compound in the cinnamon extract, it was found that the zone of inhibition of *trans*-cinnamaldehyde against *P. aeruginosa* (14.82 mm) and *K. pneumoniae* (18.45 mm) was lower than the of the whole extract, while against *E. coli* (24.39 mm), the zone of inhibition was higher compared to cinnamon extract against [29]. As mentioned above, this compound could have antimicrobial activity and be enhanced by other bioactive compounds in the cinnamon extract. Because of this, the isolated bioactive compound *trans*-cinnamaldehyde was used in a uropathogenic *E. coli* colonization in C57BL/6 female mice to reproduce a UTI. Female mice were supplemented in the feed with *trans*-cinnamaldehyde at 0.1, 0.2, and 0.4% for 14 days. On day 10, mice were infected with *E. coli* through transurethral inoculation. It is observed that *trans*-cinnamaldehyde reduced pathogen populations in the bladder and urethra in a concentration-dependent manner [30].

Moreover, it is described that aqueous *C. zeylanicum* extract (0.1 g/mL) has antimicrobial activity against isolated pathogens isolated from the urine of patients with UTIs such as *E. coli*, *K. pneumoniae*, *S. aureus*, *Enterobacter spp*, *P. aeruginosa*, *S. typhi*, and *S. flexneri*.

Furthermore, this aqueous cinnamon extract has moderate antifungal activity against *Aspergillus niger* and *Candida albicans* compared to ketoconazole. Nevertheless, due to the significant extraction of *trans*-cinnamaldehyde, the EO cinnamon extract has more antifungal activity than the aqueous extract [26]. Finally, the EO of cinnamon has MIC and MCB values of 0.125% and 0.25%, respectively, against *K. pneumoniae* isolated from patient urine samples and has good efficacy against this biofilm produced by this Gram-negative bacterium [31].

Table 1. Antimicrobial activity of cinnamon bark extracts.

Cinnamon Specie	Type of Extract	Phytochemicals	Uropathogen	MIC	MBC	Diameter of the Inhibition Zone (mm)	Ref.
<i>C. cassia</i>	Essential oil	<i>trans</i> -cinnamaldehyde, cinnamic acid, eugenol, benzaldehyde	<i>E. coli</i>	26–35 mg/mL	ND	26–38	[28]
			<i>P. aeruginosa</i>	12–19 mg/mL	ND	12–19	
			<i>P. mirabilis</i>	30–39 mg/mL	ND	30–39	
<i>C. zeylanicum</i>	Essential oil	<i>trans</i> -cinnamaldehyde, cinnamic acid, eugenol, benzaldehyde	<i>K. pneumoniae</i>	27–32 mg/mL	ND	27–32	[27]
			<i>P. aeruginosa</i>	0.11–0.2%	0.1125–1.8%	ND	
NS	Essential oil	<i>trans</i> -cinnamaldehyde, cinnamic acid, eugenol, benzaldehyde	<i>E. coli</i>	1 mg/mL	4 mg/mL	19.2	[25]
			<i>S. aureus</i>	1 mg/mL	2 mg/mL	28.7	
<i>C. verum</i>	Essential oil	<i>trans</i> -cinnamaldehyde, cinnamic acid, eugenol	<i>K. pneumoniae</i>	0.125%	0.25%	ND	[31]
<i>C. zeylanicum</i>	Ethanollic extract	Tannins, Flavonoids, anthraquinones, saponins	<i>E. coli</i>	ND	ND	11.72	[29]
			<i>K. pneumoniae</i>	ND	ND	25.50	
			<i>P. aeruginosa</i>	ND	ND	23.25	
	Ethanollic extract	Tannins, Flavonoids, anthraquinones, saponins	<i>P. aeruginosa</i>	10 mg/mL	20 mg/mL	12.3	
			<i>K. pneumoniae</i>	20 mg/mL	40 mg/mL	15.3	
			<i>S. aureus</i>	10 mg/mL	20 mg/mL	12.5	
<i>C. verum</i>	Dichloromethane extract	Flavonoids, anthraquinones, alkaloids, saponins	<i>P. aeruginosa</i>	20 mg/mL	40 mg/mL	10.0	[32]
			<i>K. pneumoniae</i>	20 mg/mL	40 mg/mL	12.3	
			<i>S. aureus</i>	5 mg/mL	10 mg/mL	11.5	
	Hexane extract	Tannins, alkaloids, flavonoids, anthraquinones, saponins	<i>P. aeruginosa</i>	10 mg/mL	20 mg/mL	10.5	
			<i>K. pneumoniae</i>	20 mg/mL	20 mg/mL	14.5	
			<i>S. aureus</i>	5 mg/mL	10 mg/mL	15.0	

ND: not determined; NS: not specified in the article. MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration.

3. Clove

Clove (*Syzygium aromaticum*, syn. *Eugenia caryophyllata*) is a plant used for centuries as a food preservative and for many medicinal purposes. It belongs to the family of Myrtaceae, the subfamily Myrtoideae, and the tribe Syzygieae [33]. It is native to Maluku Island in Indonesia. However, today it is cultivated in various parts of the world, especially in countries with tropical and subtropical environments, such as Indonesia, Sri Lanka, India, Tanzania, Malaysia, Madagascar, and Pakistan [18]. Its dried buttons (flowers that have not yet opened) are called cloves or gyrofles and are used as a spice in kitchens worldwide [34]. In Mexican cuisine, cloves are widely used to season sweet and salty foods. In salty stews, it is

included whole or ground in moles, marinades, and other dishes. As for desserts, it is used above all in fruit syrups such as guava candy.

Cloves are a valuable source of phenolic compounds such as glycosides, flavonoids (kaempferol and quercetin), saponins, tannins, and EOs. Gallic acid is the phenolic acid with the highest concentration (783.50 mg/100 g fresh weight), although researchers also find caffeic, ferulic, and salicylic acids in smaller quantities [35]. However, the main bioactive component of cloves is eugenol [2-methoxy-4-(2-propenyl) phenol], an allyl chain substituted guaiac that is a member of the allylbenzene class of chemical compounds [36], and is present in concentrations ranging from 9381.70 to 14,650.00 mg/100 g fresh plant weight [35].

In medicine, various therapeutic properties have been attributed to clove, including antifungal, antibacterial, antiviral, anti-inflammatory, antioxidant, hepatoprotective, antistress, antidiabetic, antinociceptive, anesthetic, and even anticancer activities [34]. Clove has also been widely used to treat UTIs due to its wide range of antimicrobial activities against Gram-positive and Gram-negative bacteria [37][38][39][40][41]. **Table 2** shows the antimicrobial activity of the different clove extracts.

Among the most used clove extracts to treat UTIs is clove oil, an aromatic oil extracted from the buds and leaves of *S. aromaticum* trees. It is traditionally obtained by hydrodistillation, steam distillation, or solvent extraction. These processes are inexpensive but can induce thermal degradation, hydrolysis, and water solubilization of some fragrance components [42][43]. Some authors have also carried out clove oil extraction with CO₂, which offers significant advantages over traditional methods. For example, the higher percentage of eugenol active antioxidant ingredients and a shorter extraction time, among others [42].

Clove oil has been highly successful against the bacteria responsible for UTIs. For example, it has been reported that after 8 h of treatment with clove oil, the population of *E. coli* and *S. aureus* is reduced by 99.999% and 99.9999%, respectively [38]. Additionally, in a study conducted with 60 clinical isolates from the urine of UTIs patients, clove EO was found to be more effective against *E. coli* strains than against *K. pneumoniae* strains. This is because the growth inhibition of *E. coli* was 24.5 (22.75–28) mm, while for *K. pneumoniae* it was only 22 (20–24) mm [37]. In fact, clove oil has been reported to kill *E. coli* resistant to recommended antibiotics [44].

The efficacy of EOs differs from one type of oil to another and from the target bacteria, depending on their structure (Gram-positive and Gram-negative bacteria) [45][46]. However, in a study comparing clove oil with cinnamon, bell pepper, thyme, oregano, and rosemary oils, clove oil was reported to be the most effective in inhibiting the growth of *S. typhi*, *S. aureus*, and *P. aeruginosa* [47]. Furthermore, it has been observed that mixing clove oil vapor with cinnamon oil vapor antagonistically inhibits the growth of *E. coli*. In contrast, both oils exerted a synergistic effect for inhibiting *Listeria monocytogenes*, *Bacillus cereus*, and *Yersinia enterocolitica*, when the maximum inhibition concentrations are used [48].

So far, there are few studies on the antibacterial mechanism of clove oil, especially at the molecular level. However, previous studies report that clove oil could be destroying the integrity of cell membranes, which triggers the egress of biological macromolecules and intracellular enzymes and interferes with protein synthesis [49][50]. Clove oil may also affect bacteria by slowing respiratory metabolism. Clove oil treatment has decreased the intracellular ATP of *E. coli* and *S. aureus* by up to 76.23% and 71.55%, respectively. In addition, in this same study, a decrease in nucleic acids was observed, indicating that clove oil affects the permeability of the cell membrane [38]. In another study on *L. monocytogenes*, clove oil was reported to reduce the activity of three key enzymes (isocitrate dehydrogenase, citrate synthase, and α -ketoglutarate dehydrogenase) in the citric acid cycle pathway, affecting the content of metabolites in the pathway. In addition, it has been shown that eugenol, the main component of clove oil, can change the structure of DNA through the formation of eugenol-DNA chimeras [38].

Another preparation that has been used against UTIs is the phytochemical extraction of the clove spice, which can be carried out by aqueous-ethanolic maceration. Previous studies have shown that 80% ethanol effectively extracts most bioactive phytochemical compounds, especially flavonoids [51]. In fact, a study comparing extraction with different solvents in spices reported that the 80% ethanol extraction method has the highest inhibition towards Gram-negative and Gram-positive bacteria [52].

To prepare the ethanolic extract of cloves, the spices are washed with sterile water and subsequently dried at 40 °C. Then, the clove is ground with a blender to a fine powder. Finally, a maceration with 80% ethanol is carried out, and the filtrate is concentrated using a rotary evaporator [53][54].

A recent study demonstrated that ethanolic extract of clove (2000 μ g) exhibited broad-spectrum inhibition against Gram-negative and Gram-positive UTIs-causing pathogens: *P. mirabilis* (19.7 mm), *Staphylococcus epidermidis* (18 mm), *S.*

aureus (14.7 mm), *E. coli* (12.7 mm), *K. pneumoniae* (12.3 mm) (depending on the size of the inhibition halo) [54]. Interestingly, the comparison between ethanolic clove extract and commercial clove EO revealed that the former demonstrated more potent antimicrobial and antioxidant properties at a similar concentration of eugenol. However, Gas Chromatography/Mass Spectrometry (GC/MS) indicates that the ethanolic extract has a lower concentration of eugenol than the EO, suggesting that eugenol is not the only compound responsible for the antimicrobial effect observed for the ethanolic extract [54].

In another study where 221 Gram-negative bacteria were isolated and the production of b-lactamases, enzymes responsible for resistance to b-lactam antibiotics, was analyzed, it was reported that the ethanolic extract of cloves was effective against all Gram-negative isolates. However, the best antibacterial activity was shown against *P. mirabilis* species with an inhibition halo of 19 mm. Likewise, it was found that the ethanolic extract of cloves has a different antibacterial potential depending on the Gram-negative uropathogenic [39].

In another study, aqueous and ethanolic extracts of clove, cinnamon, and garlic were prepared and tested for their antibacterial efficacy against isolated *E. coli*. Clove extracts were shown to have one of the best antibacterial activities against UTIs strains according to their mean values of the zone of inhibition (13.33 mm). The combined effect of 10% plant extracts with antibiotics such as resistance drugs ampicillin, imipenem, ciprofloxacin, norfloxacin, and nalidixic acid was also tested and showed a pattern of susceptibility with increasing inhibition zone diameter in three UTIs strains [5]. Therefore, researchers could say that the use of ethanolic clove extract to treat UTIs could be complementary to the use of antibiotics due to its additive effect with them.

There are no studies on the antibacterial mechanism of the ethanolic extract of clove, although it could be suspected that it acts the same or similar to the EO. Until now, the antibacterial activity of the ethanolic extract has only been attributed to its antioxidant properties. A recent study reported that the EC₅₀ of DPPH (1,1-diphenyl-2-picrylhydrazyl), ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid)), and reducing power assay for the ethanolic extract content of clove was 0.037 mg/mL, 0.68 mg/mL, and 0.44 mg/mL, respectively [54].

Finally, it is essential to mention that the consumption of cloves has been declared safe for humans. Clove crude EO is classified as generally considered safe (GRAS) by the US Food and Drug Administration [55]. Acute and chronic toxicity studies with clove oil conclude that there are no adverse effects in albino rats [56]. Additionally, an aqueous extract of dried clove buds (known as 'Clovinol'), rich in polyphenols, was found to be safe in rats [57]. Furthermore, eugenol is rapidly absorbed, metabolized in the liver, and eliminated within 24 h when consumed orally [58]. However, eugenol can be toxic in children under two years of age in relatively small amounts (5–10 mL) [59]. Additionally, if cloves are consumed or used excessively topically or by an allergic person may experience side effects. For example, oral intake of cloves may cause lactic acidosis, nausea, numbness, dizziness, or tiredness [60]. Furthermore, it can lead to liver problems associated with stomach pain, clay-colored stools, dark urine, and sometimes jaundice [61]. If applied topically, it could cause itchy rashes with mild skin irritation, swollen or bleeding gums, erection problems, and delayed ejaculation [60]. Previously, the World Health Organization (WHO) set the daily human intake of clove oil at 2.5 mg/kg body weight for humans [62].

In short, clove extracts can be used to develop a new antimicrobial drug that is the need of the hour. However, more research is required on the mechanisms of action, identification, and characterization of bioactive molecules, particularly their antibacterial activities in vivo against human pathogens.

Table 2. Antimicrobial activity of *S. aromaticum* extracts.

Type of Extract	Phytochemicals	Uropathogen	MIC	MBC	Diameter of the Inhibition Zone (mm)	Ref.
Clove oil	Eugenol, β-caryophyllene, vanillin, crategolic acid, bicornin, galotanic acid, methyl salicylate eugenin, kaempferol, ramnetin and eugenitin, oleanolic acid, stigmasterol, campesterol, and various sesquiterpenes	<i>E. coli</i>	0.5 mg/mL	0.5 mg/mL	ND	[38]
		<i>S. aureus</i>	0.5 mg/mL	0.5 mg/mL	ND	

Type of Extract	Phytochemicals	Uropathogen	MIC	MBC	Diameter of the Inhibition Zone (mm)	Ref.
Clove oil	Eugenol, β -caryophyllene, vanillin, crategolic acid, bicornin, galotanic acid, methyl salicylate eugenin, kaempferol, ramnetin and eugenitin, oleanolic acid, stigmasterol, campesterol, and various sesquiterpenes	<i>A. baumannii</i>	ND	ND	28	[63]
		<i>P. aeruginosa</i>	ND	ND	17	
		<i>E. faecalis</i>	ND	ND	25	
		<i>S. aureus</i>	ND	ND	20	
Clove oil	Eugenol, β -caryophyllene, vanillin, crategolic acid, bicornin, galotanic acid, methyl salicylate eugenin, kaempferol, ramnetin and eugenitin, oleanolic acid, stigmasterol, campesterol, and various sesquiterpenes	<i>E. coli</i> isolated from UTIs patients	2.1 to 3.1 mg/mL	3.1 to 4.2 mg/mL	ND	[44]
		Antibiotic-resistant <i>E. coli</i>	2.6 mg/mL	3.7 mg/mL	ND	
Clove oil	Eugenol, β -caryophyllene, vanillin, crategolic acid, bicornin, galotanic acid, methyl salicylate eugenin, kaempferol, ramnetin and eugenitin, oleanolic acid, stigmasterol, campesterol, and various sesquiterpenes	<i>E. coli</i> isolated from UTIs patients	5.5 μ L/mL and 0.55 μ L/mL *	ND	24.5 mm	[37]
		<i>K. pneumoniae</i> isolated from UTIs patients	5.5 μ L/mL and 0.55 μ L/mL *	ND	22 mm	
Ethanolic extract	Eugenol, glycosides, flavonoids, saponins, tannins, and essential oils.	<i>S. aureus</i>	5 mg/mL	10 mg/mL	11.4	[64]
		<i>P. aeruginosa</i>	5 mg/mL	12.5 mg/mL	9.2	
		<i>E. coli</i>	0.39 mg/mL	0.19 mg/mL	17	
		<i>K. pneumoniae</i>	0.78 mg/mL	0.39 mg/ml	16	
		<i>Enterobacter</i> species	0.78 mg/mL	0.39 mg/mL	17	
Ethanolic extract	Eugenol, glycosides, flavonoids, saponins, tannins, and essential oils.	<i>Citrobacter</i> Species	0.39 mg/mL	0.19 mg/mL	18	[39]
		<i>P. mirabilis</i>	0.39 mg/mL	0.19 mg/mL	19	
		<i>P. aeruginosa</i>	1.56 mg/mL	0.78 mg/mL	14	
		<i>A. baumannii</i>	0.78 mg/mL	0.39 mg/mL	18	
		<i>P. mirabilis</i>	ND	ND	19.7	
Ethanolic extract	Eugenol, glycosides, flavonoids, saponins, tannins, and essential oils.	<i>S. epidermidis</i>	ND	ND	18	[54]
		<i>K. pneumoniae</i>	ND	ND	12.3	
		<i>E. coli</i>	ND	ND	12.7	
		<i>S. aureus</i>	ND	ND	14.7	

* Depending on the strain. ND: not determined; MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration.

4. Cumin

Cumin (*Cuminum cyminum* L.) is an aromatic plant that belongs to the Apiaceae family, Apioideae subfamily, Scandiceae tribe, and Daucinae subtribe [65]. It has a branched and ribbed stem, leaves divided into filaments and strongly lobed, small white or pink flowers, and ovate or spindle-shaped fruits, light brown or light grey. The seeds are ovoid, and two

grains are connected in one body; one side is raised and ribbed, and the other is flat, brown in color, fragrant in odor, and pungent in taste [66]. The seeds are mainly used as a seasoning or flavoring agent for different culinary purposes [67]. The seed's EO is used in abundance to make soups, stews, sausages, cheeses, pickles, curries, meats, and chutneys. Furthermore, the seeds are widely used in the perfume industry due to their intense aroma [68]. Additionally, it is used in medical preparations such as toothpaste, mouthwashes, and soaps [67].

Today, cumin is produced in countries such as Chile, Mexico, Syria, Egypt, Morocco, Turkey, Iran, Tajikistan, Uzbekistan, and China, where India accounts for 70% of world production and 90% of consumption [69]. Particularly in Mexico, it was popularized by the Spanish, who traditionally used it to make blood sausage and other dishes, and it quickly became part of the local cuisine due to its spicy flavor [70].

Cumin seed contains 22.27 to 23.80% total lipids and 2.4 to 5.0% EO (volatile). It also has organic acids such as aspartic, benzoic, citric, malic, propionic, tartaric, ascorbic, maleic, oxalic, and fumaric acids, phenols such as salicylic, cinnamic, gallic, p-hydroxybenzoic acid, hydroquinone, resorcinol and flavonoids such as rutin, quercetin, and coumarin [69][71][72]. Limonene, α - and β -pinene, 1, 8-cineole, o- and p-cymene, α - and γ -terpinene, safranal, and linalool are compounds that are also found in cumin seed. However, cuminaldehyde, cymene, and terpenoids are the main bioactive components, although the EO, in addition to cuminaldehyde, also has paracymene [66][69].

Cumin has different preparations. The most used is the EO extracted from the seeds with the hydrodistillation method. For extraction with this method, the dried and macerated seeds are placed in a distillation apparatus with distilled water for three to four hours. The oil is then extracted and stored in dark vials until use [73][74][75]. The main components of cumin can also be extracted using different solvents such as methanol, acetone, butanol, alcohol, and even water [75][76][77].

In medicine, cumin extracts have been used as an antiseptic, antispasmodic, anticancer, and treatment for digestive disorders, colic, and dyspeptic headaches [78]. In addition, *Cuminum cyminum* seeds have been shown to possess significant biological properties, such as antibacterial and antifungal activity [75]. Cumin has played an important role in UTIs due to its antimicrobial activity against Gram-positive and Gram-negative bacteria [74][75][77]. **Table 3** shows the antimicrobial activity of the different cumin extracts.

Table 3. Antimicrobial activity of *Cuminum cyminum* extracts.

Type of Extract	Phytochemicals	Uropathogen	MIC	MBC	Diameter of the Inhibition Zone (mm)	Ref.
Essential oil	Cuminaldehyde, α -thujene, α,β -pinene, p-cymene, γ -terpinene, cumin oils	<i>K. pneumoniae</i>	0.8–3.5 $\mu\text{g/mL}$	ND	ND	[74]
Essential oil	Cuminaldehyde, α -thujene, α,β -pinene, p-cymene, γ -terpinene, cumin oils	<i>E. coli</i>	10–50 ppm and 100–250 ppm *	ND	ND	[73]

Type of Extract	Phytochemicals	Uropathogen	MIC	MBC	Diameter of the Inhibition Zone (mm)	Ref.
Essential oil	Cuminaldehyde, α -thujene, α,β -pinene, <i>p</i> -cymene, γ -terpinene, cumin oils	<i>E. coli</i>	0.25 mg/mL	0.5 mg/mL	23	[75]
		<i>K. pneumoniae</i>	0.25 mg/mL	0.5 mg/mL	22	
		<i>p. aeruginosa</i>	0.25 mg/mL	0.5 mg/mL	20	
		<i>S. agalactiae</i>	0.25 mg/mL	0.5 mg/mL	21	
		group A streptococci	0.015 mg/mL	0.03 mg/mL	20	
		<i>E. faecalis</i>	0.125 mg/mL	0.25 mg/mL	20	
		<i>S. epidermidis</i>	0.25 mg/mL	0.5 mg/mL	10	
		<i>S. aureus</i>	ND	ND	7	
		<i>S. saprophyticus</i>	0.25 mg/mL	0.5 mg/mL	20	
Essential oil	Cuminaldehyde, α -thujene, α,β -pinene, <i>p</i> -cymene, γ -terpinene, cumin oils	<i>S. aureus</i>	1161 μ g/mL	ND	45	[52]
		<i>P. aeruginosa</i>	84.97 μ g/mL	ND	8	
		<i>K. pneumoniae</i>	204.87 μ g/mL	ND	12	
		<i>E. coli</i>	7.219 μ g/mL	ND	52	
		<i>E. coli</i>	0.125 mg/mL	0.25 mg/mL	22	
		<i>K. pneumoniae</i>	0.125 mg/mL	0.25 mg/mL	22	
		<i>P. aeruginosa</i>	0.25 mg/mL	0.5 mg/mL	20	
		<i>S. agalactiae</i>	ND	ND	7	
Ethanollic extract	ND	group A streptococci	0.125 mg/mL	0.25 mg/mL	23	[75]
		<i>E. faecalis</i>	0.125 mg/mL	0.25 mg/mL	23	
		<i>S. epidermidis</i>	0.125 mg/mL	0.25 mg/mL	25	
		<i>S. aureus</i>	0.125 mg/mL	0.25 mg/mL	20	
		<i>S. saprophyticus</i>	0.25 mg/mL	0.5 mg/mL	23	
		<i>E. coli</i>	ND	ND	26	
		<i>K. pneumonia</i>	ND	ND	22	
		<i>S. saprophyticus</i>	ND	ND	25	
		<i>P. mirabilis</i>	ND	ND	21.5	
Aqueous-ethanollic (30/70) extract	Carbohydrates, flavonoids, protein, alkaloids, phenols					[77]

* Depending on the isolated strain; ND: not determined; MIC: minimum inhibitory concentration; MBC: minimum bactericidal concentration.

Cumin EO has potent antimicrobial activity even against strains of *E. coli* resistant to multiple drugs, including tetracycline, erythromycin, amoxicillin, ceftazidime, and cefixime. A study carried out on 12 strains of *E. coli* isolated from the urine of

patients hospitalized with UTIs showed that cumín EO had a differential inhibitory effect between the different isolates. Approximately 24.9% of *E. coli* isolates showed low MICs (<50 ppm), while 41.6% had moderate MICs (100 ppm), and 16.6% of the isolates had high MICs (250 ppm) [73]. Likewise, another study observed that cumín oil and methanolic extract have better antibacterial activity in uropathogenic isolates than amoxicillin; however, this did not happen with other antibiotics. The EO and the methanolic extract were tested against *E. coli*, *K. pneumoniae*, *P. aeruginosa*, *S. agalactiae*, group A *streptococci*, *E. faecalis*, *S. epidermidis*, *S. aureus*, and *S. saprophyticus*, isolated from samples of 95 UTIs patients, but without malignant diseases, diabetes and immunosuppression [75]. In another study carried out in 2016, the effect of cumín oil was compared with chamomile and clove oil. Cumín oil was found to inhibit most bacteria. Furthermore, it was more effective when used with some antibiotics, suggesting that it could be an adjunctive treatment [52].

The mechanism by which cumín EO exerts its antibacterial effects remains unclear. However, it has been reported to cause cell wall damage or changes in outer membrane proteins; these effects could be attributed to the molecular characteristics of the aldehydes present [74][79][80]. It should be noted that bacterial DNA degradation is not a proven antibacterial mechanism for cumín EO. It was previously reported that cumín AE could not induce DNA degradation of the R plasmid of clinical isolates of *K. pneumoniae* [74]. In addition, the aqueous-ethanolic extract (30/70) of cumín has been reported to have significant antibacterial and antioxidant activities [77].

Finally, researchers must consider that cumín use has side effects, including contact dermatitis, respiratory reactions, and liver cancer (above dietary levels) [81]. Patients with stomach ulcers, liver disorders, and pregnant or lactating women should use cumín with caution. Patients should also be aware of the use of drugs similar to cumín, including antibiotics, anticancer drugs, antifungals, anti-inflammatory drugs, antioxidants, anticonvulsants, cholesterol, and lipid-lowering drugs, estrogen and gastrointestinal drugs, pesticides, iron, morphine, opioids, osteoporosis agents, analgesics and phytoestrogens [66].

In summary, cumín extracts can be used as antibiotics against UTIs-inducing pathogens, even those resistant to drugs. However, it is important to continue updating the information on cumín in combination with antibiotics to enhance the inhibitory effect of uropathogens and study the possible mechanisms behind this protection.

References

1. Yang, X.; Chen, H.; Zheng, Y.; Qu, S.; Wang, H.; Yi, F. Disease burden and long-term trends of urinary tract infections: A worldwide report. *Front. Public Health* 2022, 10, 888205.
2. Ballesteros-Monreal, M.G.; Arenas-Hernández, M.M.P.; Barrios-Villa, E.; Juárez, J.; Álvarez-Ainza, M.L.; Taboada, P.; De la Rosa-López, R.; Bolado-Martínez, E.; Valencia, D. Bacterial Morphotypes as Important Trait for Uropathogenic *E. coli* Diagnostic; a Virulence-Phenotype-Phylogeny Study. *Microorganisms* 2021, 9, 2381.
3. Bien, J.; Sokolova, O.; Bozko, P. Role of Uropathogenic *Escherichia coli* Virulence Factors in Development of Urinary Tract Infection and Kidney Damage. *Int. J. Nephrol.* 2012, 2012, 681473.
4. Asadi Karam, M.R.; Habibi, M.; Bouzari, S. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against Uropathogenic *Escherichia coli*. *Mol. Immunol.* 2019, 108, 56–67.
5. Naseer, F. Antibacterial Activity of Medicinal Plants (Clove, Cinnamon, Garlic) Extracts and their Combined Effect with Antibiotics in Urinary Tract Infection Caused by *Escherichia coli*. *Int. J. Pharm. Pharmacol.* 2018, 2, 128.
6. Kim, A.; Ahn, J.H.; Choi, W.S.; Park, H.K.; Kim, S.; Paick, S.H.; Kim, H.G. What is the Cause of Recurrent Urinary Tract Infection? Contemporary Microscopic Concepts of Pathophysiology. *Int. Neurourol. J.* 2021, 25, 192–201.
7. Murray, B.O.; Flores, C.; Williams, C.; Flusberg, D.A.; Marr, E.E.; Kwiatkowska, K.M.; Charest, J.L.; Isenberg, B.C.; Rohn, J.L. Recurrent Urinary Tract Infection: A Mystery in Search of Better Model Systems. *Front. Cell. Infect. Microbiol.* 2021, 11, 691210.
8. Lee, J.-H.; Kim, Y.-G.; Lee, J. Carvacrol-rich oregano oil and thymol-rich thyme red oil inhibit biofilm formation and the virulence of uropathogenic *Escherichia coli*. *J. Appl. Microbiol.* 2017, 123, 1420–1428.
9. Lucas, M.; Macías, J.; Cañarte, J. Perfil de sensibilidad a antimicrobianos como principal criterio para la selección del tratamiento de infecciones del tracto urinario. *Revisión Sistemática. Rev. Kasmera* 2021, 49, 1–11.
10. Nabavi, S.; Di Lorenzo, A.; Izadi, M.; Sobarzo-Sánchez, E.; Daglia, M.; Nabavi, S. Antibacterial Effects of Cinnamon: From Farm to Food, Cosmetic and Pharmaceutical Industries. *Nutrients* 2015, 7, 7729–7748.
11. Vasconcelos, N.G.; Croda, J.; Simionatto, S. Antibacterial mechanisms of cinnamon and its constituents: A review. *Microb. Pathog.* 2018, 120, 198–203.

12. Rasool, N.; Saeed, Z.; Pervaiz, M.; Ali, F.; Younas, U.; Bashir, R.; Bukhari, S.M.; Mahmood Khan, R.R.; Jelani, S.; Sika ndar, R. Evaluation of essential oil extracted from ginger, cinnamon and lemon for therapeutic and biological activities. *Biocatal. Agric. Biotechnol.* 2022, 44, 102470.
13. Mbaveng, A.T.; Kuete, V. Cinnamon species. In *Medicinal Spices and Vegetables from Africa*; Elsevier: Amsterdam, The Netherlands, 2017; pp. 385–395.
14. Rao, P.V.; Gan, S.H. Cinnamon: A Multifaceted Medicinal Plant. *Evid. -Based Complement. Altern. Med.* 2014, 2014, 642942.
15. Błaszczuk, N.; Rosiak, A.; Kałużna-Czaplińska, J. The Potential Role of Cinnamon in Human Health. *Forests* 2021, 12, 648.
16. Kowalska, J.; Tyburski, J.; Matysiak, K.; Jakubowska, M.; Łukaszuk, J.; Krzyżmińska, J. Cinnamon as a Useful Preventive Substance for the Care of Human and Plant Health. *Molecules* 2021, 26, 5299.
17. Jayaprakasha, G.K.; Rao, L.J.M. Chemistry, Biogenesis, and Biological Activities of *Cinnamomum zeylanicum*. *Crit. Rev. Food Sci. Nutr.* 2011, 51, 547–562.
18. Hussain, S.; Rahman, R.; Mushtaq, A.; Zerey-Belaskri, A. El Clove: A review of a precious species with multiple uses. *Int. J. Chem. Biochem. Sci.* 2017, 11, 129–133.
19. Yun, J.-W.; You, J.-R.; Kim, Y.-S.; Kim, S.-H.; Cho, E.-Y.; Yoon, J.-H.; Kwon, E.; Jang, J.-J.; Park, J.-S.; Kim, H.-C.; et al. In vitro and in vivo safety studies of cinnamon extract (*Cinnamomum cassia*) on general and genetic toxicology. *Regul. Toxicol. Pharmacol.* 2018, 95, 115–123.
20. Gu, D.-T.; Tung, T.-H.; Jiesisibieke, Z.L.; Chien, C.-W.; Liu, W.-Y. Safety of Cinnamon: An Umbrella Review of Meta-Analyses and Systematic Reviews of Randomized Clinical Trials. *Front. Pharmacol.* 2022, 12, 790901.
21. Modi, P.I.; Parikh, J.K.; Desai, M.A. Sonohydrodistillation: Innovative approach for isolation of essential oil from the bark of cinnamon. *Ind. Crops Prod.* 2019, 142, 111838.
22. Kumar, V.; Marković, T.; Emerald, M.; Dey, A. Herbs: Composition and dietary importance. In *Encyclopedia of Food and Health*; Elsevier: Amsterdam, The Netherlands, 2016; pp. 332–337.
23. Pereira, W.A.; Pereira, C.D.S.; Assunção, R.G.; da Silva, I.S.C.; Rego, F.S.; Alves, L.S.R.; Santos, J.S.; Nogueira, F.J.R.; Zagmignan, A.; Thomsen, T.T.; et al. New Insights into the Antimicrobial Action of Cinnamaldehyde towards *Escherichia coli* and Its Effects on Intestinal Colonization of Mice. *Biomolecules* 2021, 11, 302.
24. Waty, S.; Suryanto, D. Yurnaliza Antibacterial activity of cinnamon ethanol extract (*cinnamomum burmannii*) and its application as a mouthwash to inhibit streptococcus growth. *IOP Conf. Ser. Earth Environ. Sci.* 2018, 130, 012049.
25. Zhang, Y.; Liu, X.; Wang, Y.; Jiang, P.; Quek, S. Antibacterial activity and mechanism of cinnamon essential oil against *Escherichia coli* and *Staphylococcus aureus*. *Food Control* 2016, 59, 282–289.
26. Thiagarajan, S.; John, S. Antimicrobial activity of *Cinnamomum zeylanicum* aqueous extract against bacteria and fungi responsible for urinary tract infection. *Int. J. Health Allied Sci.* 2020, 9, 229.
27. Utcharyakiat, I.; Surassmo, S.; Jaturanpinyo, M.; Khuntayaporn, P.; Chomnawang, M.T. Efficacy of cinnamon bark oil and cinnamaldehyde on anti-multidrug resistant *Pseudomonas aeruginosa* and the synergistic effects in combination with other antimicrobial agents. *BMC Complement. Altern. Med.* 2016, 16, 158.
28. Zenati, F.; Benbelaid, F.; Khadir, A.; Bellahsene, C.; Bendahou, M. Antimicrobial effects of three essential oils on multidrug resistant bacteria responsible for urinary infections. *J. Appl. Pharm. Sci.* 2014, 4, 015–018.
29. Dhore, M.R.; Jha, A.R. Antimicrobial activity of *Allium cepa* and *Cinnamomum zeylanicum* against common bacteria causing urinary tract infections: In vitro study. *Int. J. Basic Clin. Pharmacol.* 2019, 8, 1185.
30. Narayanan, A.; Muiyarakandy, M.S.; Mooyottu, S.; Venkitanarayanan, K.; Amalaradjou, M.A.R. Oral supplementation of trans -cinnamaldehyde reduces uropathogenic *Escherichia coli* colonization in a mouse model. *Lett. Appl. Microbiol.* 2017, 64, 192–197.
31. Rafeeq, H.; Sharba, Z. Study the Effect of Cinnamon and Tea Tree Oils on Biofilm Formation of *Klebsiella Pneumoniae*. *J. Appl. Sci. Nanotechnol.* 2022, 2, 16–26.
32. Idris, F.Z.; Habibu, U.A. In-vitro antibacterial activity of cinnamon bark extracts on clinical multi-drug resistant (mdr) *Staphylococcus aureus*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa* isolates. *Bayero J. Pure Appl. Sci.* 2021, 14, 38–44.
33. Cock, E.; Cheesman, M. Plants of the genus *syzygium* (Myrtaceae): A review on ethnobotany, medicinal properties, and phytochemistry. In *Bioactive Compounds of Medicinal Plants*; Goyal, M.R., Ed.; Apple Academic Press: Palm Bay, FL, USA, 2018; p. 50.

34. Ayushi; Khan, U.A.; Danish, S.M.; Mohammad; Parveen, U. A review on biological and therapeutic uses of *Syzygium aromaticum* Linn. (Clove): Based on phyto-chemistry and pharmacological evidences. *Int. J. Bot. Stud.* 2020, 5, 33–39.
35. Shan, B.; Cai, Y.Z.; Sun, M.; Corke, H. Antioxidant Capacity of 26 Spice Extracts and Characterization of Their Phenolic Constituents. *J. Agric. Food Chem.* 2005, 53, 7749–7759.
36. National Center for Biotechnology Information PubChem Compound Summary for CID 3314, Eugenol. Available online: <https://pubchem.ncbi.nlm.nih.gov/compound/Eugenol> (accessed on 1 December 2022).
37. Băicuș, A.; Mattuzzi, F.C.; Paraschiv, A.M.; Dinu, R.-S.; Dumitrescu, M.C.; Marinescu, A.A.; Ionescu, D.; Dragos, D. Antibacterial Activity of Clove, Oregano, Thyme, Eucalyptus, and Tea Tree Essential Oils against *Escherichia coli* and *Klebsiella pneumoniae* strains. *Rev. Rom. Med. Lab.* 2022, 30, 327–338.
38. Cui, H.; Zhao, C.; Lin, L. The specific antibacterial activity of liposome-encapsulated Clove oil and its application in tofu. *Food Control* 2015, 56, 128–134.
39. Faujdar, S.; Bisht, D.; Sharma, A. Antibacterial activity of *Syzygium aromaticum* (clove) against uropathogens producing ESBL, MBL, and AmpC beta-lactamase: Are we close to getting a new antibacterial agent? *J. Fam. Med. Prim. Care* 2020, 9, 180.
40. Mytle, N.; Anderson, G.L.; Doyle, M.P.; Smith, M.A. Antimicrobial activity of clove (*Syzygium aromaticum*) oil in inhibiting *Listeria monocytogenes* on chicken frankfurters. *Food Control* 2006, 17, 102–107.
41. Nuñez, L.; D'Aquino, M. Microbicide activity of clove essential oil (*Eugenia caryophyllata*). *Braz. J. Microbiol.* 2012, 43, 1255–1260.
42. Guan, W.; Li, S.; Yan, R.; Tang, S.; Quan, C. Comparison of essential oils of clove buds extracted with supercritical carbon dioxide and other three traditional extraction methods. *Food Chem.* 2007, 101, 1558–1564.
43. Hatami, T.; Johnner, J.C.F.; Zabot, G.L.; Meireles, M.A.A. Supercritical fluid extraction assisted by cold pressing from clove buds: Extraction performance, volatile oil composition, and economic evaluation. *J. Supercrit. Fluids* 2019, 144, 39–47.
44. Dąbrowski, M.; Sienkiewicz, M.; Zielińska-Bliźniewska, H.; Dąbrowska, M.; Seredyńska, M.; Kochan, E. Antibiotic resistance among *Escherichia coli* urinary isolates and their susceptibility to clove essential oil. *Ann. Univ. Mariae Curie-Skłodowska Sect. C Biol.* 2018, 71, 41.
45. Raut, J.S.; Karuppaiyil, S.M. A status review on the medicinal properties of essential oils. *Ind. Crops Prod.* 2014, 62, 250–264.
46. Roy, S.; Chaurvedi, P.; Chowdhary, A. Evaluation of antiviral activity of essential oil of *Trachyspermum Ammi* against Japanese encephalitis virus. *Pharmacogn. Res.* 2015, 7, 263.
47. Swamy, M.K.; Akhtar, M.S.; Sinniah, U.R. Antimicrobial Properties of Plant Essential Oils against Human Pathogens and Their Mode of Action: An Updated Review. *Evidence-Based Complement. Altern. Med.* 2016, 2016, 3012462.
48. Goñi, P.; López, P.; Sánchez, C.; Gómez-Lus, R.; Becerril, R.; Nerín, C. Antimicrobial activity in the vapour phase of a combination of cinnamon and clove essential oils. *Food Chem.* 2009, 116, 982–989.
49. Devi, K.P.; Nisha, S.A.; Sakthivel, R.; Pandian, S.K. Eugenol (an essential oil of clove) acts as an antibacterial agent against *Salmonella typhi* by disrupting the cellular membrane. *J. Ethnopharmacol.* 2010, 130, 107–115.
50. Rhayour, K.; Bouchikhi, T.; Tantaoui-Elaraki, A.; Sendide, K.; Remmal, A. The Mechanism of Bactericidal Action of Oregano and Clove Essential Oils and of Their Phenolic Major Components on *Escherichia coli* and *Bacillus subtilis*. *J. Essential Oil Res.* 2003, 15, 356–362.
51. Valle, D.L.; Cabrera, E.C.; Puzon, J.J.M.; Rivera, W.L. Antimicrobial Activities of Methanol, Ethanol and Supercritical CO₂ Extracts of Philippine Piper beetle L. on Clinical Isolates of Gram Positive and Gram Negative Bacteria with Transferable Multiple Drug Resistance. *PLoS ONE* 2016, 11, e0146349.
52. Mahmoud, A.M.; El-Baky, R.M.A.; Ahmed, A.B.F.; Fadl, G. Antibacterial Activity of Essential Oils and in Combination with Some Standard Antimicrobials against Different Pathogens Isolated from Some Clinical Specimens. *Am. J. Microbiol. Res.* 2016, 4, 16–25.
53. Rakshit, M.; Ramalingam, C. Screening and Comparison of Antibacterial Activity of Indian Spices. *J. Exp. Sci.* 2010, 1, 33–36.
54. Rosarior, V.L.; Lim, P.S.; Wong, W.K.; Yue, C.S.; Yam, H.C.; Tan, S.-A. Antioxidant-rich Clove Extract, A Strong Antimicrobial Agent against Urinary Tract Infections-causing Bacteria in vitro. *Trop. Life Sci. Res.* 2021, 32, 45–63.
55. Code of Federal Regulations. Chapter I. Food and Drug Administration. Subchapter E. Animal drugs, feeds, and related products. In *Food and Drugs*; 2015; p. 21 CFR 582.20. Available online: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=582.20> (accessed on 1 December 2022).

56. Shalaby, S.; El-Din, M.; Abo-Donia, S.; Mettwally, M.; Attia, Z. Toxicological effects of essential oils from *Eucalyptus globules* and clove *Eugenia caryophyllus* on albino rats. *Polish J. Environ. Stud.* 2011, 20, 429–434.
57. Vijayasteltar, L.; Nair, G.G.; Maliakel, B.; Kuttan, R.; Krishnakumar, I.M. Safety assessment of a standardized polyphenolic extract of clove buds: Subchronic toxicity and mutagenicity studies. *Toxicol. Rep.* 2016, 3, 439–449.
58. Cortés-Rojas, D.F.; de Souza, C.R.F.; Oliveira, W.P. Clove (*Syzygium aromaticum*): A precious spice. *Asian Pac. J. Trop. Biomed.* 2014, 4, 90–96.
59. Hartnoll, G.; Moore, D.; Douek, D. Near fatal ingestion of oil of cloves. *Arch. Dis. Child.* 1993, 69, 392–393.
60. Slameňová, D.; Horváthová, E.; Wsóllová, L.; Šramková, M.; Navarová, J. Investigation of anti-oxidative, cytotoxic, DNA-damaging and DNA-protective effects of plant volatiles eugenol and borneol in human-derived HepG2, Caco-2 and VH 10 cell lines. *Mutat. Res. Toxicol. Environ. Mutagen.* 2009, 677, 46–52.
61. Doleželová, P.; Mácová, S.; Plhalová, L.; Pištěková, V.; Svobodová, Z. The acute toxicity of clove oil to fish *Danio rerio* and *Poecilia reticulata*. *Acta Vet. Brno* 2011, 80, 305–308.
62. FAO/WHO. Evaluation of Certain Food Additives and Contaminants: Twenty-Sixth Report of the Joint FAO/WHO Expert Committee on Food Additives ; WHO: Geneva, Switzerland, 1982.
63. Abdullah, B.H.; Hatem, S.F.; Jumaa, W. A Comparative Study of the Antibacterial Activity of Clove and Rosemary Essential Oils on Multidrug Resistant Bacteria. *Pharm. Biosci. J.* 2015, 3, 18–22.
64. Mostafa, A.A.; Al-Askar, A.A.; Almaary, K.S.; Dawoud, T.M.; Sholkamy, E.N.; Bakri, M.M. Antimicrobial activity of some plant extracts against bacterial strains causing food poisoning diseases. *Saudi J. Biol. Sci.* 2018, 25, 361–366.
65. National Center for Biotechnology Information PubChem Taxonomy Summary for TaxonomyBob 52462, *Cuminum cyminum*. Available online: <https://pubchem.ncbi.nlm.nih.gov/taxonomy/Cuminum%20cyminum> (accessed on 19 December 2022).
66. Singh, R.P.; Gangadharappa, H.V.; Mruthunjaya, K. *Cuminum cyminum*—A Popular Spice: An Updated Review. *Pharmacogn. J.* 2017, 9, 292–301.
67. Siow, H.-L.; Gan, C.-Y. Extraction, identification, and structure–activity relationship of antioxidative and α -amylase inhibitory peptides from cumin seeds (*Cuminum cyminum*). *J. Funct. Foods* 2016, 22, 1–12.
68. Singh, N.; Yadav, S.S.; Kumar, S.; Narashiman, B. A review on traditional uses, phytochemistry, pharmacology, and clinical research of dietary spice *Cuminum cyminum* L. *Phyther. Res.* 2021, 35, 5007–5030.
69. Rajput, R.P.S.; Paramakrishnan, N.; Gangadharappa, H.V. Cumin (*Cuminum cyminum* L.) Seed. In *Oilseeds: Health Attributes and Food Applications*; Springer Singapore: Singapore, 2021; pp. 507–516.
70. Animal Gourmet Comino, la Semilla del Sabor Virreinal. Available online: <https://www.animalgourmet.com/2015/04/17/5-Osaboresmexicanos-comino-la-semilla-del-sabor-virreinal/#:~:text=En%20M%C3%A9xico%20fue%20popularizada%20por,su%20sabor%20picante%20y%20acre> (accessed on 19 December 2022).
71. El-kani, M.H.; Golmohammad, F.; Mirza, M.; Rowshanzamir, S. Extraction of volatile oil from cumin (*Cuminum cyminum* L.) With superheated water. *J. Food Process Eng.* 2007, 30, 255–266.
72. Iacobellis, N.S.; Lo Cantore, P.; Capasso, F.; Senatore, F. Antibacterial Activity of *Cuminum cyminum* L. and *Carum carvi* L. Essential Oils. *J. Agric. Food Chem.* 2005, 53, 57–61.
73. Bokaeian, M.; Shiri, Y.; Bazi, S.; Saeidi, S.; Sahi, Z. Antibacterial activities of *Cuminum cyminum* Linn. Essential Oil Against Multi-Drug resistant *Escherichia coli*. *Int. J. Infect.* 2014, 1, e18739.
74. Sattari, M.; Bigdeli, M.; Derakhshan, S. Effect of cumin (*Cuminum cyminum*) seed essential oil on biofilm formation and plasmid Integrity of *Klebsiella pneumoniae*. *Pharmacogn. Mag.* 2010, 6, 57.
75. Saeed, Y.; Dadashi, M.; Eslami, G.; Goudarzi, H.; Taheri, S.; Fallah, F. Evaluation of Antimicrobial Activity of *Cuminum cyminum* Essential Oil and Extract against Bacterial Strains Isolated from Patients with Symptomatic Urinary Tract Infection. *Nov. Biomed.* 2016, 4, 147–152.
76. Gupta, A.D.; Bansal, V.K.; Babu, V.; Maithil, N. Chemistry, antioxidant and antimicrobial potential of nutmeg (*Myristica fragrans* Houtt). *J. Genet. Eng. Biotechnol.* 2013, 11, 25–31.
77. Rehman, J.U.; Iqbal, A.; Mahmood, A.; Asif, H.M.; Mohiuddin, E.; Akram, M. Phytochemical analysis, antioxidant and antibacterial potential of some selected medicinal plants traditionally utilized for the management of urinary tract infection. *Pak. J. Pharm. Sci.* 2021, 34, 1056–1062.
78. Prakash, E.; Gupta, D.K. Cytotoxic Activity of Ethanolic Extract of *Cuminum cyminum* Linn against Seven Human Cancer Cell Line. *Univers. J. Agric. Res.* 2014, 2, 27–30.

79. Niu, C.; Gilbert, E.S. Colorimetric Method for Identifying Plant Essential Oil Components That Affect Biofilm Formation and Structure. *Appl. Environ. Microbiol.* 2004, 70, 6951–6956.
80. Gutmann, L.; Williamson, R.; Moreau, N.; Kitzis, M.-D.; Collatz, E.; Acar, J.F.; Goldstein, F.W. Cross-Resistance to Nalidixic Acid, Trimethoprim, and Chloramphenicol Associated with Alterations in Outer Membrane Proteins of *Klebsiella*, *Enterobacter*, and *Serratia*. *J. Infect. Dis.* 1985, 151, 501–507.
81. Johri, R. *Cuminum cyminum* and *Carum carvi*: An update. *Pharmacogn. Rev.* 2011, 5, 63.

Retrieved from <https://encyclopedia.pub/entry/history/show/98525>